EP4166539A1 — Nitrile-containing compounds for use as medicaments
Assigned to Pfizer Inc · Expires 2023-04-19 · 3y expired
What this patent protects
The invention relates to the use as a medicament of a compound of formula Ih-1a, Ih-1b, Ih-1c, Ii-1a, Ii-1b, Ii-1c, Ij-1a, Ij-1b, Ij-1c, Ik-a, Ik-b or Ik-c:wherein R<sup>4</sup> is defined herein; or a solvate or hydrate thereof, or a pharmaceutically acceptable salt …
USPTO Abstract
The invention relates to the use as a medicament of a compound of formula Ih-1a, Ih-1b, Ih-1c, Ii-1a, Ii-1b, Ii-1c, Ij-1a, Ij-1b, Ij-1c, Ik-a, Ik-b or Ik-c:wherein R<sup>4</sup> is defined herein; or a solvate or hydrate thereof, or a pharmaceutically acceptable salt of said compound, solvate or hydrate. These compounds are useful in treating coronavirus infections such as COVID-19.
Drugs covered by this patent
- Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.